Insider Buying: Embecta (NASDAQ:EMBC) CEO Acquires 30,000 Shares of Stock

Embecta Corp. (NASDAQ:EMBC) CEO Devdatt Kurdikar purchased 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were acquired at an average price of $4.70 per share, for a total transaction of $141,000.00. Following the completion of the purchase, the chief executive officer directly owned 804,919 shares in the company, valued at $3,783,119.30. This represents a 3.87% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Embecta Price Performance

Embecta stock traded up $0.41 during trading hours on Thursday, reaching $5.16. The company had a trading volume of 659,113 shares, compared to its average volume of 1,586,592. The firm has a market cap of $292.08 million, a price-to-earnings ratio of 3.49 and a beta of 0.81. Embecta Corp. has a 12-month low of $2.77 and a 12-month high of $15.55. The company has a 50-day moving average price of $3.43 and a 200 day moving average price of $6.46.

Embecta (NASDAQ:EMBC) last issued its earnings results on Friday, August 7th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.27 by $0.29. The company had revenue of $271.70 million for the quarter, compared to the consensus estimate of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The firm’s revenue for the quarter was down 8.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. As a group, research analysts expect that Embecta Corp. will post 1.85 earnings per share for the current year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th will be paid a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Thursday, August 27th. Embecta’s dividend payout ratio is presently 2.70%.

Hedge Funds Weigh In On Embecta

A number of institutional investors and hedge funds have recently modified their holdings of EMBC. Larson Financial Group LLC raised its holdings in Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after buying an additional 1,574 shares during the period. Wexford Capital LP purchased a new position in Embecta during the third quarter worth $94,000. Tower Research Capital LLC TRC boosted its stake in Embecta by 542.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after buying an additional 6,224 shares during the period. iSAM Funds UK Ltd bought a new position in Embecta during the third quarter valued at $115,000. Finally, One Wealth Advisors LLC bought a new position in Embecta during the second quarter valued at $33,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on EMBC shares. Weiss Ratings cut shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. BTIG Research downgraded Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Wall Street Zen cut Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Finally, Bank of America reduced their price target on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research report on Monday, May 18th. Three research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Embecta presently has an average rating of “Reduce” and a consensus target price of $11.00.

Embecta News Roundup

Here are the key news stories impacting Embecta this week:

• Negative Sentiment: The lawsuit, filed in federal court in New Jersey, alleges that Embecta and certain executives misrepresented the commercial stability of the company’s insulin pen-needle business. The allegations concern investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, and have not been proven in court. EMBC Securities Lawsuit: Embecta Securities Fraud Class Action is Pending
• Negative Sentiment: A wave of investor-alert releases from SBS Law, Kaplan Fox, DJS Law, Rosen Law Firm, Hagens Berman, Faruqi & Faruqi and other firms highlights an August 17, 2026 deadline for investors to seek lead-plaintiff status. The repeated announcements increase the visibility of the legal issue and could raise concerns about potential financial, management and reputational costs for Embecta. Kaplan Fox Alerts Investors of a Securities Class Action Against Embecta
• Neutral Sentiment: The announcements primarily seek potential plaintiffs and do not represent a new court ruling, settlement or regulatory finding. Embecta’s previously reported quarterly results showed adjusted earnings and revenue above consensus, but revenue declined 8.1% year over year; the company’s FY 2026 earnings guidance remains $1.80–$1.90 per share.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.